ADIM
ZYME icon

Alpha DNA Investment Management’s Zymeworks ZYME Stock Holding History

Alpha DNA Investment Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-92,822
Closed -$802K – 228
2023
Q2 		$802K Buy
+92,822
New +$831K 0.27% 97

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Alpha DNA Investment Management's ZYME Position: Q3 2023 in Review

Alpha DNA Investment Management sold out of Zymeworks (ZYME) in Q3 2023, closing a stake of 92,822 shares — an estimated $802K sold.

Alpha DNA Investment Management first reported a position in ZYME in Q2 2023 and held it in 1 quarter. The position peaked at $802K in Q2 2023. 139 funds tracked by Wall St. Rank hold ZYME as of Q3 2023.

  • Alpha DNA Investment Management reported no remaining Zymeworks position as of Q3 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 92,822 Zymeworks shares in Q3 2023, an estimated $802K.
  • Alpha DNA Investment Management first reported a position in Zymeworks in Q2 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Zymeworks position peaked at $802K in Q2 2023.
  • 139 funds tracked by Wall St. Rank held Zymeworks as of Q3 2023.

Based on Alpha DNA Investment Management's 13F filing for Q3 2023, filed 7 Nov 2023.